HeartSciences Inc.HSCSEarnings & Financial Report
Meril Life Sciences is an Indian multinational medical device company, with headquarters in Vapi, Gujarat, India. It was founded in 2006 and is a part of the Bilakhia Group. The company is engaged in the manufacturing of vascular intervention devices, orthopedic implants, robotics, endosurgery, ENT products and in-vitro diagnostics. Meril Life Sciences operates in over 150 countries and has employed 10000 people, as of 2024.
HSCS Q2 FY2026 Key Financial Metrics
Revenue
$2.4K
Gross Profit
$1.4K
Operating Profit
$-2.1M
Net Profit
$-2.4M
Gross Margin
58.3%
Operating Margin
-85713.2%
Net Margin
-97179.4%
YoY Growth
N/A
EPS
$-0.85
HeartSciences Inc. Q2 FY2026 Financial Summary
HeartSciences Inc. reported revenue of $2.4K for Q2 FY2026, with a net profit of $-2.4M (down 12.9% YoY) (-97179.4% margin). Cost of goods sold was $1.0K, operating expenses totaled $2.1M.
Key Financial Metrics
| Total Revenue | $2.4K |
|---|---|
| Net Profit | $-2.4M |
| Gross Margin | 58.3% |
| Operating Margin | -85713.2% |
| Report Period | Q2 FY2026 |
HeartSciences Inc. Annual Revenue by Year
HeartSciences Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $5.2K).
HeartSciences Inc. Quarterly Revenue & Net Profit History
HeartSciences Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2026 | $2.4K | — | $-2.4M | -97179.4% |
| Q1 FY2026 | $1.9K | — | $-2.1M | -108157.6% |
| Q3 FY2025 | $0 | — | $-2.5M | N/A |
| Q3 FY2024 | $14.7K | +653.8% | $-1.6M | -11182.4% |
| Q2 FY2024 | $3.9K | — | $-1.7M | -44830.2% |
| Q4 FY2023 | $0 | — | $-1.6M | N/A |
| Q3 FY2023 | $1.9K | -39.1% | $-1.3M | -68826.4% |
| Q2 FY2023 | $0 | — | $-1.8M | N/A |
Income Statement
| Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q3 2024 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1950 | $0 | $3900 | $14700 | $0 | $1900 | $2419 |
| YoY Growth | N/A | -39.1% | N/A | N/A | 653.8% | N/A | N/A | N/A |
Balance Sheet
| Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q3 2024 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $4.8M | $3.5M | $3.3M | $2.4M | $10.8M | $5.7M | $6.4M | $6.0M |
| Liabilities | $3.7M | $3.7M | $3.1M | $4.0M | $2.2M | $3.9M | $3.3M | $1.8M |
| Equity | $1.1M | $-257912 | $230557 | $-1.6M | $8.6M | $1.8M | $3.1M | $4.2M |
Cash Flow
| Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q3 2024 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.1M | $-1.0M | $-1.9M | $-988187 | $-2.1M | $-1.6M | $-2.0M | $-2.3M |